FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006980919> ?p ?o ?g. }

• W2006980919 endingPage "467" @default.
• W2006980919 startingPage "459" @default.
• W2006980919 abstract "Background The carbonaceous oral adsorbent AST-120 slows the deterioration of kidney function in patients with advanced chronic kidney disease (CKD). However, information about AST-120 in patients with less severe stages of CKD is lacking. Study Design Randomized controlled trial. Setting & Participants 75 medical facilities, 460 patients with CKD with serum creatinine (sCr) concentrations less than 5.0 mg/dL (not undergoing dialysis). Intervention Random assignment to either a low-protein diet and antihypertensive medication in the control group or that treatment combined with AST-120 (6 g/d). Outcomes & Measurements Composite primary end point: doubling of sCr level, increase in sCr level to 6.0 mg/dL or more, need for dialysis or transplantation, or death. Secondary outcomes: adverse events and changes in estimated creatinine clearance (CCr) rate, proteinuria (protein in milligrams per day), and quality of life. Results Mean sCr level was 2.66 mg/dL and estimated CCr was 22.4 mL/min in both groups. During 56 weeks, numbers of primary end-point events (43 for control versus 42 for AST-120) and event-free survival (P = 0.9) did not differ between groups. Gastrointestinal adverse events were less common in the control group than the AST-120 group (2 versus 32 events). Estimated CCr decreased more in the control group than in the AST-120 group (−0.15 versus −0.12 mL/min/y; P = 0.001). Median proteinuria changed from protein of 1,162 to 1,167 mg/d in the control group versus 1,102 to 906 mg/d in the AST-120 group (P = 0.2). Limitation Infrequent primary end-point events. Conclusion AST-120 did not substantially slow the progression of kidney disease in patients with moderate to severe CKD during 1 year. The carbonaceous oral adsorbent AST-120 slows the deterioration of kidney function in patients with advanced chronic kidney disease (CKD). However, information about AST-120 in patients with less severe stages of CKD is lacking. Randomized controlled trial. 75 medical facilities, 460 patients with CKD with serum creatinine (sCr) concentrations less than 5.0 mg/dL (not undergoing dialysis). Random assignment to either a low-protein diet and antihypertensive medication in the control group or that treatment combined with AST-120 (6 g/d). Composite primary end point: doubling of sCr level, increase in sCr level to 6.0 mg/dL or more, need for dialysis or transplantation, or death. Secondary outcomes: adverse events and changes in estimated creatinine clearance (CCr) rate, proteinuria (protein in milligrams per day), and quality of life. Mean sCr level was 2.66 mg/dL and estimated CCr was 22.4 mL/min in both groups. During 56 weeks, numbers of primary end-point events (43 for control versus 42 for AST-120) and event-free survival (P = 0.9) did not differ between groups. Gastrointestinal adverse events were less common in the control group than the AST-120 group (2 versus 32 events). Estimated CCr decreased more in the control group than in the AST-120 group (−0.15 versus −0.12 mL/min/y; P = 0.001). Median proteinuria changed from protein of 1,162 to 1,167 mg/d in the control group versus 1,102 to 906 mg/d in the AST-120 group (P = 0.2). Infrequent primary end-point events. AST-120 did not substantially slow the progression of kidney disease in patients with moderate to severe CKD during 1 year." @default.
• W2006980919 created "2016-06-24" @default.
• W2006980919 creator A5007508591 @default.
• W2006980919 creator A5018869061 @default.
• W2006980919 creator A5019990331 @default.
• W2006980919 creator A5045969631 @default.
• W2006980919 creator A5046418468 @default.
• W2006980919 creator A5049605722 @default.
• W2006980919 creator A5065151254 @default.
• W2006980919 creator A5071555943 @default.
• W2006980919 creator A5078733914 @default.
• W2006980919 creator A5081294000 @default.
• W2006980919 date "2009-09-01" @default.
• W2006980919 modified "2023-10-13" @default.
• W2006980919 title "Effect of a Carbonaceous Oral Adsorbent on the Progression of CKD: A Multicenter, Randomized, Controlled Trial" @default.
• W2006980919 cites W1968328692 @default.
• W2006980919 cites W1968830449 @default.
• W2006980919 cites W1975268626 @default.
• W2006980919 cites W2000366267 @default.
• W2006980919 cites W2003240711 @default.
• W2006980919 cites W2021806010 @default.
• W2006980919 cites W2024714913 @default.
• W2006980919 cites W2040246202 @default.
• W2006980919 cites W2056191975 @default.
• W2006980919 cites W2057804361 @default.
• W2006980919 cites W2059628172 @default.
• W2006980919 cites W2060093750 @default.
• W2006980919 cites W2093121077 @default.
• W2006980919 cites W2100893920 @default.
• W2006980919 cites W2133991735 @default.
• W2006980919 cites W2152189242 @default.
• W2006980919 cites W2154169784 @default.
• W2006980919 doi "https://doi.org/10.1053/j.ajkd.2009.05.011" @default.
• W2006980919 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19615804" @default.
• W2006980919 hasPublicationYear "2009" @default.
• W2006980919 type Work @default.
• W2006980919 sameAs 2006980919 @default.
• W2006980919 citedByCount "136" @default.
• W2006980919 countsByYear W20069809192012 @default.
• W2006980919 countsByYear W20069809192013 @default.
• W2006980919 countsByYear W20069809192014 @default.
• W2006980919 countsByYear W20069809192015 @default.
• W2006980919 countsByYear W20069809192016 @default.
• W2006980919 countsByYear W20069809192017 @default.
• W2006980919 countsByYear W20069809192018 @default.
• W2006980919 countsByYear W20069809192019 @default.
• W2006980919 countsByYear W20069809192020 @default.
• W2006980919 countsByYear W20069809192021 @default.
• W2006980919 countsByYear W20069809192022 @default.
• W2006980919 countsByYear W20069809192023 @default.
• W2006980919 crossrefType "journal-article" @default.
• W2006980919 hasAuthorship W2006980919A5007508591 @default.
• W2006980919 hasAuthorship W2006980919A5018869061 @default.
• W2006980919 hasAuthorship W2006980919A5019990331 @default.
• W2006980919 hasAuthorship W2006980919A5045969631 @default.
• W2006980919 hasAuthorship W2006980919A5046418468 @default.
• W2006980919 hasAuthorship W2006980919A5049605722 @default.
• W2006980919 hasAuthorship W2006980919A5065151254 @default.
• W2006980919 hasAuthorship W2006980919A5071555943 @default.
• W2006980919 hasAuthorship W2006980919A5078733914 @default.
• W2006980919 hasAuthorship W2006980919A5081294000 @default.
• W2006980919 hasConcept C126322002 @default.
• W2006980919 hasConcept C126894567 @default.
• W2006980919 hasConcept C159641895 @default.
• W2006980919 hasConcept C168563851 @default.
• W2006980919 hasConcept C197934379 @default.
• W2006980919 hasConcept C203092338 @default.
• W2006980919 hasConcept C2778063415 @default.
• W2006980919 hasConcept C2778653478 @default.
• W2006980919 hasConcept C2779561371 @default.
• W2006980919 hasConcept C2779978075 @default.
• W2006980919 hasConcept C2780091579 @default.
• W2006980919 hasConcept C2780306776 @default.
• W2006980919 hasConcept C71924100 @default.
• W2006980919 hasConcept C90924648 @default.
• W2006980919 hasConceptScore W2006980919C126322002 @default.
• W2006980919 hasConceptScore W2006980919C126894567 @default.
• W2006980919 hasConceptScore W2006980919C159641895 @default.
• W2006980919 hasConceptScore W2006980919C168563851 @default.
• W2006980919 hasConceptScore W2006980919C197934379 @default.
• W2006980919 hasConceptScore W2006980919C203092338 @default.
• W2006980919 hasConceptScore W2006980919C2778063415 @default.
• W2006980919 hasConceptScore W2006980919C2778653478 @default.
• W2006980919 hasConceptScore W2006980919C2779561371 @default.
• W2006980919 hasConceptScore W2006980919C2779978075 @default.
• W2006980919 hasConceptScore W2006980919C2780091579 @default.
• W2006980919 hasConceptScore W2006980919C2780306776 @default.
• W2006980919 hasConceptScore W2006980919C71924100 @default.
• W2006980919 hasConceptScore W2006980919C90924648 @default.
• W2006980919 hasIssue "3" @default.
• W2006980919 hasLocation W20069809191 @default.
• W2006980919 hasLocation W20069809192 @default.
• W2006980919 hasOpenAccess W2006980919 @default.
• W2006980919 hasPrimaryLocation W20069809191 @default.
• W2006980919 hasRelatedWork W2025805266 @default.
• W2006980919 hasRelatedWork W2104709702 @default.
• W2006980919 hasRelatedWork W2122079536 @default.
• W2006980919 hasRelatedWork W2165568411 @default.

• next